US5324831A - Phosphoramidite reagent for chemical synthesis of modified DNA - Google Patents

Phosphoramidite reagent for chemical synthesis of modified DNA Download PDF

Info

Publication number
US5324831A
US5324831A US07/178,153 US17815388A US5324831A US 5324831 A US5324831 A US 5324831A US 17815388 A US17815388 A US 17815388A US 5324831 A US5324831 A US 5324831A
Authority
US
United States
Prior art keywords
compound
azacytidine
phosphoramidite
dihydro
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/178,153
Inventor
Victor E. Marquez
Amanda J. Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, AS REPRESENTED BY SECRETARY US Department OF HEALTH AND HUMAN SERVICES
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to US07/178,153 priority Critical patent/US5324831A/en
Priority to IL89827A priority patent/IL89827A0/en
Priority to CA000595701A priority patent/CA1330960C/en
Priority to AU33681/89A priority patent/AU625295B2/en
Priority to JP1504376A priority patent/JPH0692435B2/en
Priority to PCT/US1989/001395 priority patent/WO1989009779A1/en
Assigned to UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MARQUEZ, VICTOR E.
Assigned to UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY U.S. DEPT. OF HEALTH AND HUMAN SERVICES reassignment UNITED STATES OF AMERICA, THE, AS REPRESENTED BY THE SECRETARY U.S. DEPT. OF HEALTH AND HUMAN SERVICES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GODDARD, AMANDA J.
Application granted granted Critical
Publication of US5324831A publication Critical patent/US5324831A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to the synthesis of DNA containing modified cytosine bases, namely 5-6-dihydro-5-azacytosine and 5-azacytosine, and more specifically to a reagent for use in the chemical synthesis of modified DNA which allows the incorporation of said bases at specific sites of a sequence.
  • polynucleotide fragments having a desired nucleotide sequence is a useful tool in both research and applied molecular biology.
  • Short synthetic polynucleotides, or oligonucleotides are useful as adaptors or linkers in joining longer DNA segments, and as hybridization probes and DNA synthesis primers.
  • Longer polynucleotides can be constructed from shorter segments having overlapping cohesive ends and used as structural genes, regulatory regions such as promoters, terminators, operators, and the like. It is thus of great interest to provide convenient automatic techniques for producing synthetic DNA fragments with high yields in a relatively short time.
  • nucleotide sequences such as DNA
  • DNA DNA
  • One of these reactions is the postreplicative modification of newly synthesized DNA by the selective methylation of certain cytosine residues which is performed enzymatically by a specific DNA methylase.
  • An understanding of the factors governing the formation of specific methylation patterns in eucaryotic DNA is very important if we are to understand the mechanisms of gene expression.
  • the synthesis is usually carried out either on a solid-phase substrate or in solution.
  • Solid-phase synthesis relies on sequential addition of mononucleotides to a growing chain attached at one end to the substrate.
  • the solid phase permits easy separation of the reactants, but the method requires excess quantities of reactants and usually provides only small quantities (less than 1 mg) of the desired sequence.
  • Solution phase synthesis while it requires lesser amounts of the expensive reagents and can provide larger quantities of the product sequence, requires isolation and purification of the intermediate product after every addition. Virtually all automated polynucleotide systems rely on solid phase synthesis.
  • phosphite-triester method was greatly improved by the use of N,N-dialkylamino phosphites (amidites) which are more stable than the phosphor-chlorodite intermediates initially employed. While the phosphite-triester method is often favored because of the greater yield at each nucleotide addition, the phosphate-triester method is also suitable for automated polynucleotide synthesis.
  • the tight bed column is tightly packed with the solid-phase support and the reactants are introduced either in a single pass or by a recirculating stream.
  • Loose bed columns have been introduced to alleviate these problems partially. By slowly passing the reactant through the column, higher mass transfer rates are achieved and utilization of the expensive reactants is improved. Also, channelling is reduced, since the solid phase packing will shift to equalize the flow profile therethrough.
  • the support matrix is held in an enclosed vessel.
  • Reactants are introduced and the vessel contents agitated, typically by bubbling an inert gas through the liquid in the reactor. While such a system can provide very efficient utilization of the reactants by increasing the retention time in the reactor, relatively large volumes of the reactant and solvent are necessary to fill the reactor.
  • Urdea et al. in U.S. Pat. No. 4,517,338, disclose a method and system for sequential modification of a linear polymeric molecule attached to a dispersed solid phase support by adding individual nucleotides in a predetermined order to a nucleotide chain.
  • the dispersed solid phase is retained within a reactor zone which is provided with access ports for the introduction and removal of reagents. Reagents are selectively delivered to the reactor zone through at least one of the access ports by a reagent manifold.
  • the protected 5,6-dihydro-5-azacytidine phosphoramidite, compound 9 has a very stable triazine ring, analogous to its parent nucleoside.
  • Scheme 1 outlines the synthesis of 5-azacytidine phosphoramidite starting with 5-azacytosinedeoxyribose. Protection with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, followed by borohydride reduction of compound 2, gave the desired dihydro analog, compound 3, after purification by silica gel flash chromatography with 5% methanol in ethyl acetate. The 1 H-NMR spectrum of compound 3 shows the newly generated C-6 methylene protons as an AB quartet centered at 4.40 ppm.
  • FIG. 1 shows the fragmentation pattern for dimer 12 obtained by negative ion FAB mass spectroscopy
  • FIG. 2 shows autoradiography of synthetic oligonucleotides obtained after 5'-end labelling and polyacrylamide gel electrophoresis.
  • Lane 1 (CA)3, hexamer marker
  • compound 7 was prepared by removing the sugar tetraisopropyldisiloxane protective group with tetrabutylammonium fluoride at room temperature in THF. This compound was purified by simple extraction in methylene chloride after the reaction mixture was reduced to dryness and partitioned between water and methylene chloride to give compound 7 as a foam in 59% yield.
  • Scheme 6 shows the phosphitylation of compound 8 in the presence of diisopropylamine in methylene chloride with chloro(diisopropylamino)methoxy phosphine to give 71% yield of compound 9 as a glassy substance after purification by silica gel column chromatography with 25% ethyl acetate in hexane.
  • the phosphoramidite of the present invention is used in a typical condensation reaction to synthesize DNA.
  • the phosphoramidite was mixed with 3'-O-acetyl thymidine, compound 10, as shown in Scheme 7, in acetonitrile in the presence of tetrazole as the condensing catalyst, according to the procedure of Pfleiderer and Schwarz (Tetrahedron Letters, 25: 5513, 1984).
  • Thin layer chromatography showed complete reaction after fifteen minutes, and the dimeric product was immediately oxidized in situ with a mixture of iodine, lutidine, THF, and water to give a quantative yield of the fully protected dimer phosphate, compound 11.
  • two decamers shown in FIG. 2, lanes 4 and 5, in which the cytosine base at positions 3 and 6 was replaced by the 5,6-dihydro-5-azacytosine moiety, were synthesized in an Applied Biosystems model 380A automated DNA synthesizer. Based on the trityl assay data, the stepwise yield was 98.5% and 98.4%, respectively, compared to 99.09% for the unmodified decamer (FIG. 2, lane 3).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

5,6-dihydro-5-azacytidine phosphoramidite is useful in the synthesis of oligonucleotides and DNA containing dihydro-5-aza- and 5-azacytosine bases. The modified oligonucleotides which contain 5-azacytosine residues at specific sites can be used to determine the mechanism of selective gene activation and the relationship existing between the presence of the triazine base and inhibition of DNA methylation.

Description

FIELD OF THE INVENTION
The present invention relates to the synthesis of DNA containing modified cytosine bases, namely 5-6-dihydro-5-azacytosine and 5-azacytosine, and more specifically to a reagent for use in the chemical synthesis of modified DNA which allows the incorporation of said bases at specific sites of a sequence.
BACKGROUND OF THE INVENTION
The ability to synthesize polynucleotide fragments having a desired nucleotide sequence is a useful tool in both research and applied molecular biology. Short synthetic polynucleotides, or oligonucleotides, are useful as adaptors or linkers in joining longer DNA segments, and as hybridization probes and DNA synthesis primers. Longer polynucleotides can be constructed from shorter segments having overlapping cohesive ends and used as structural genes, regulatory regions such as promoters, terminators, operators, and the like. It is thus of great interest to provide convenient automatic techniques for producing synthetic DNA fragments with high yields in a relatively short time.
As the understanding of the function, structure, and chemical makeup of nucleotide sequences, such as DNA, has evolved, so too has the awareness of the practicalities and feasibilities of genetic engineering. These engineering efforts, however, require a complete understanding of the chemical and biological reactions in cells. One of these reactions is the postreplicative modification of newly synthesized DNA by the selective methylation of certain cytosine residues which is performed enzymatically by a specific DNA methylase. An understanding of the factors governing the formation of specific methylation patterns in eucaryotic DNA is very important if we are to understand the mechanisms of gene expression.
Basic to such genetic engineering efforts is the synthesis of desired nucleotide chains from single mononucleotides. In this regard, electromechanical apparatus has been developed for synthesizing desired oligonucleotide sequences via the sequential linking of desired bases to a starting nucleotide.
At present, a variety of approaches for polynucleotide synthesis are available. These approaches can be characterized based on several criteria. First, the synthesis is usually carried out either on a solid-phase substrate or in solution. Solid-phase synthesis relies on sequential addition of mononucleotides to a growing chain attached at one end to the substrate. The solid phase permits easy separation of the reactants, but the method requires excess quantities of reactants and usually provides only small quantities (less than 1 mg) of the desired sequence. Solution phase synthesis, while it requires lesser amounts of the expensive reagents and can provide larger quantities of the product sequence, requires isolation and purification of the intermediate product after every addition. Virtually all automated polynucleotide systems rely on solid phase synthesis.
There are presently two synthesis chemistries in widespread used for automated polynucleotide synthesis. The triester method, as described by Catlin and Cramer J. Org. Chem. 38: 245-250 (1973) and Itakura et al., Can. J. Chem. 51: 3649-3651 (1973) which relies on the addition of suitable blocked phosphate-triester intermediates which are generally inexpensive and stable. The phosphite-triester method, as described by Letsinger and Lunsford in J. Am. Chem. Soc. 98:3655 (1975) is somewhat more complex, but generally provides higher yields than the phosphate triester method. The utility of the phosphite-triester method was greatly improved by the use of N,N-dialkylamino phosphites (amidites) which are more stable than the phosphor-chlorodite intermediates initially employed. While the phosphite-triester method is often favored because of the greater yield at each nucleotide addition, the phosphate-triester method is also suitable for automated polynucleotide synthesis.
Among the reactor systems that can be used in synthesizing polynucleotides are solid-phase reactor systems which use either a tight bed column, a loose bed column, or a batch reactor. The tight bed column is tightly packed with the solid-phase support and the reactants are introduced either in a single pass or by a recirculating stream.
Loose bed columns have been introduced to alleviate these problems partially. By slowly passing the reactant through the column, higher mass transfer rates are achieved and utilization of the expensive reactants is improved. Also, channelling is reduced, since the solid phase packing will shift to equalize the flow profile therethrough.
In a batch reactor, the support matrix is held in an enclosed vessel. Reactants are introduced and the vessel contents agitated, typically by bubbling an inert gas through the liquid in the reactor. While such a system can provide very efficient utilization of the reactants by increasing the retention time in the reactor, relatively large volumes of the reactant and solvent are necessary to fill the reactor.
Urdea et al., in U.S. Pat. No. 4,517,338, disclose a method and system for sequential modification of a linear polymeric molecule attached to a dispersed solid phase support by adding individual nucleotides in a predetermined order to a nucleotide chain. The dispersed solid phase is retained within a reactor zone which is provided with access ports for the introduction and removal of reagents. Reagents are selectively delivered to the reactor zone through at least one of the access ports by a reagent manifold.
Another apparatus for programmably synthesizing selected nucleotide sequences is described in Zelinka et al., U.S. Pat. No. 4,598,049.
The well known instability of the triazine ring of 5-azacytosine deoxyribonucleoside makes it unsuitable for use as a building block in the aforementioned automated DNA syntheses. Despite this drawback, interest in the synthesis of single and double stranded DNA fragments containing 5-azacytosine residues constitutes an important goal in the understanding of the mechanism of action of this drug. DNA incorporation of 5-azacytosine in living cells has been associated with inhibition of DNA methylase activity and consequent gene activation.
Because of the well established relationship that exists between the DNA incorporation of 5-azacytosine residues and gene activation, it would be o useful to develop a methodology for the synthesis of oliqonucleotide fragments which contain this unnatural base. These modified oligonucleotides, which would contain 5,6-dihydro-5-azacytosine and 5-azacytosine residues at specific sites, could serve as tools for elucidating the mechanism of selective gene activation and the relationship that exists between the presence of these triazine bases and inhibition of DNA methylation. A direct incorporation of the phosphoramidite of 2'-deoxy-5-aza-cytidine in DNA synthesis would results in failure, since the 2'-deoxy-5-aza-cytidine is extremely sensitive to acid or alkaline conditions.
SUMMARY OF THE INVENTION
It is an object of the present invention to overcome deficiencies in the prior art, such as noted above.
It is a further object of the invention to provide a method for the synthesis of modified oligonucleotides containing either 5,6-dihydro-5-azacytosine or 5-azacytosine bases at specific sites of the sequence.
It is another object of the present invention to provide a reagent for the automated synthesis of DNA to accomplish the incorporation of 5,6-dihydro-5-azacytosine and 5-azacytosine bases.
It is also an object of the present invention to provide for a method of converting 5,6-dihydro-5azacytosine to 5-azacytosine in an oligonucleotide structure.
It is yet a further object of the present invention to provide compounds for use in studying the mechanism of selective gene activation.
The use of a phosphoramidite of 2'-deoxy-dihydro-5-aza-cytidine in DNA synthesis results in the successful formation of the desired internucleotide linkage and permits the synthesis of modified DNA fragments, since it is totally compatible with all of the chemical steps used in DNA synthesis. At the conclusion of the synthesis, a very specific and easily performed oxidation generates the desired 5-aza-cytosine moiety. Since the hydrolytic instability of the triazine ring in 5-azacytosine nucleosides is very well documented, the use of a conventional phosphoramidite derivative of 5-azacytosinedeoxyribose, compound 1, is impractical, as this would have resulted in the basecatalyzed cleavage of the triazine ring during the last deprotection step of the synthesis. The process of the present invention overcomes this problem by using a stable phosphoramidite precursor of 5-azacytosinedeoxyribose that permits regeneration of the desired 5-azacytosine base after the conclusion of the synthesis of the oligonucleotide.
The protected 5,6-dihydro-5-azacytidine phosphoramidite, compound 9, has a very stable triazine ring, analogous to its parent nucleoside.
The reactions according to the present invention are shown in the following reaction schemes: ##STR1##
Scheme 1 outlines the synthesis of 5-azacytidine phosphoramidite starting with 5-azacytosinedeoxyribose. Protection with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, followed by borohydride reduction of compound 2, gave the desired dihydro analog, compound 3, after purification by silica gel flash chromatography with 5% methanol in ethyl acetate. The 1 H-NMR spectrum of compound 3 shows the newly generated C-6 methylene protons as an AB quartet centered at 4.40 ppm. The exocyclic amino group of compound 3 was then protected as the isobutyrylamide, compound 4, and purified by silica gel flash chromatography with 50% ethyl acetate in hexane. Complete protection of the triazine ring was accomplished with the introduction of the bis(isobutyryloxy)ethylene group, performed in the same manner as for 2'-deoxyguanosine. Thus, the intermediate diol, compound 5, isolated from the reaction of compound 4 with glyoxal, was reacted with isobutyryl chloride to give compound 6, which was purified by silica gel flash chromatography with 15% ethyl acetate in hexane. Removal of the tetraisopropyldisiloxane group in compound 6 with tetrabutylammonium fluoride gave compound 7, following a simple extraction in methylene chloride/water. Protection of the 5'-hydroxyl group was accomplished by the standard procedure using 4,4'-dimethoxytrityl chloride to yield compound 8 as a crystalline solid, mp 89°-91° C. (hexane). Finally, phosphitylation of compound 8 with chloro-N,N'-diisopropylaminomethoxyphosphite gave the desired phosphoramidite, compound 9, as a white solid, mp 67°-69° C. after purification by silica gel flash chromatography with 25% ethyl acetate in hexane.
The reactivity of the new phosphoramidite, compound 9, was initially tested under the standard conditions used for DNA synthesis in a typical tetrazole-catalyzed condensation reaction with 3'-O-acetyl-thymidine, as shown in Scheme 2. After 15 minutes, the reaction was complete, and was immediately oxidized in situ to give a quantitative yield of the fully protected dimer, compound 11. Removal of the dimethoxytrityl group with trichloroacetic acid and further treatment of the residue with concentrated ammonium hydroxide yielded the fully blocked dimer, compound 12 ##STR2##
In order to test the new reagent, two decamers in which the cytosine base at positions 3 and 6 was replaced by the 5,6-dihydro-5-azacytosine moiety, were synthesized in an Applied Biosystems model 380A automated DNA synthesizer. Based on the trityl assay data, the stepwise yield was 98.5% and 98.4%, respectively, compared to 99.09% for the unmodified decamer.
The final conversion of the dihydrotriazine base to the aromatic triazine was successfully accomplished by the use of bis(trimethylsilyl)trifluoroacetamide (BSTFA) and trimethylsilyl chloride as silylating reagents, and trimethylsilyl peroxide as an oxidizing reagent. For the transformation the dimeric compound 12 was used as a model and the resulting dimer 13 was prepared in quantiative yield.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the fragmentation pattern for dimer 12 obtained by negative ion FAB mass spectroscopy
FIG. 2 shows autoradiography of synthetic oligonucleotides obtained after 5'-end labelling and polyacrylamide gel electrophoresis.
Lane 1: (CA)3, hexamer marker
Lane 2, (AT)4, octamer marker
Lane 3, TACGTCGCAG, patent decamer
Lane 4, TAXGTCGCAG, 3-modified decamer
Lane 5, TACGTXGCAG, 6-modified decamer
X=5,6-dihydro-5-azacytidine.
DETAILED DESCRIPTION OF THE INVENTION
The detailed reaction schemes are shown as follows: ##STR3##
The synthesis of phosphoramidite according to the present invention started with 2'-deoxy-5-azacytidine, compound 1. As shown in Scheme 3, the 3' and 5' hydroxy groups were simultaneously protected with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane using pyridine as solvent and base, according to the procedure of Markiewick et al. in Bull. Pol. Acad. Sci., 32: 433, 1984. This reaction proceeded in 97% yield, giving the desired compound 3 as a foam. In this and the following schemes, the tetraisopropyldisiloxane group is depicted as a semicircle joining the 3' and 5' oxygen atoms of the nucleoside.
In the subsequent step, shown in Scheme 3, the double bond was reduced either catalytically with hydrogen over palladium on carbon, or more efficiently with sodium borohydride in tetrahydrofuran. After one hour of reaction, followed by treatment with methanol and water, workup and chromatography over silica gel with 5% methanol in ethyl acetate, the desired product, compound 4, was obtained in 78% yield as a foam.
Referring to Scheme 4, the exocyclic amino function was protected at this point in 84% yield by treatment of compound 3 with isobutyryl chloride in pyridine. After a conventional workup and silica gel chromatography with 50% hexane in ethyl acetate, compound 4 was obtained as a foam.
As shown in Scheme 4, complete protection of the aglycon moiety was achieved by introducing the isobutyryloxyethylene group. Reaction of compound 4 with glyoxal, followed by treatment of the cyclized intermediate with isobutyrl chloride in anhydrous pyridine, gave compound 6 after purification by silica gel column chromatography with 15% ethyl acetate in hexane. Compound 6 was isolated as a foam in 61% yield.
Referring to Scheme 5, compound 7 was prepared by removing the sugar tetraisopropyldisiloxane protective group with tetrabutylammonium fluoride at room temperature in THF. This compound was purified by simple extraction in methylene chloride after the reaction mixture was reduced to dryness and partitioned between water and methylene chloride to give compound 7 as a foam in 59% yield.
Selective protection of the 5'-hydroxy group, as required for DNA synthesis, was accomplished by the standard procedure using 4,4'-dimethoxytrityl chloride in dry pyridine to yield compound 8 is 50% yield as crystalline solid, mp 89°-91° C.
Scheme 6 shows the phosphitylation of compound 8 in the presence of diisopropylamine in methylene chloride with chloro(diisopropylamino)methoxy phosphine to give 71% yield of compound 9 as a glassy substance after purification by silica gel column chromatography with 25% ethyl acetate in hexane.
The phosphoramidite of the present invention, compound 9, is used in a typical condensation reaction to synthesize DNA. The phosphoramidite was mixed with 3'-O-acetyl thymidine, compound 10, as shown in Scheme 7, in acetonitrile in the presence of tetrazole as the condensing catalyst, according to the procedure of Pfleiderer and Schwarz (Tetrahedron Letters, 25: 5513, 1984). Thin layer chromatography showed complete reaction after fifteen minutes, and the dimeric product was immediately oxidized in situ with a mixture of iodine, lutidine, THF, and water to give a quantative yield of the fully protected dimer phosphate, compound 11. Treatment of a solution of this dimer in dichloromethane with trichloroacetic acid removed the dimethoxytrityl group, and treatment of the residue with concentrated ammonium hydroxide at 55° C. for fifteen hour yielded the fully deblocked target dimer, as shown in Scheme 8. An analytical sample of the deblocked dimer was obtained after reversed phase chromatography on J. T. Baker C-18 silical gel, 40 micrometers, 5% methanol in water, and as shown in FIG. 1, the FAB/MS was consistent with the expected structure.
Finally, the dihydro-5-azacytidine containing dimer, compound 12, was suspended in dry acetonitrile and treated with an excess of bis(trimethylsilyl)trifluoroacetamide, trimethylsilyl chloride, and trimethylsilylperoxide under reflux overnight, as shown in Scheme 9. Oxidation to the 5-azacytidine stage took place quantitatively as assessed by the dominance of the M-H peak in the mass spectrometer at m/z 531. The workup was very simple and involved evaporation of the volatile solvent and reagent and treatment of the residue with water to deblock the remaining oxygen and nitrogen to silicon linkages. Lyophilization of the aqueous solution yielded the desired dimer, compound 13.
In order to test the utility of the new regent, two decamers, shown in FIG. 2, lanes 4 and 5, in which the cytosine base at positions 3 and 6 was replaced by the 5,6-dihydro-5-azacytosine moiety, were synthesized in an Applied Biosystems model 380A automated DNA synthesizer. Based on the trityl assay data, the stepwise yield was 98.5% and 98.4%, respectively, compared to 99.09% for the unmodified decamer (FIG. 2, lane 3).
While the invention is described above in relation to certain specific embodiments, it will be understood that many variations are possible, and that alternative materials and reagents can be used without departing from the invention. In some cases such variations and substitutions may require some experimentation, but such will only involve routine testing.
The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and therefore such adaptations and modifications are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation.

Claims (5)

What is claimed is:
1. 5,6-dihydro-5-azacytidine phosphoramidite.
2. 5,6-dihydro-5-azacytidine phosphoramidite with protecting groups on the amino groups of the azacytidine ring and on the 5' hydroxy group, wherein said protecting groups are suitable for use in the phosphoramidite synthesis of polynucleotides.
3. A compound selected from the group consisting of: ##STR4##
4. In a method for synthesizing a polynucleotide containing at least one modified cytosine base using the phosphoramidite method, wherein the improvement in said method is that the modified cytosine base is 5-azacytidine and the polynucleotide is prepared by:
a) using the phosphoramidite method to synthesize a polynucleotide containing at least one 5,6-dihydro-5-azacytidine base;
b) and selectively oxidizing said 5,6-dihydro-5-azacytidine base in the polynucleotide formed in step a) to a 5-azacytidine base.
5. The process of claim 4, wherein said selective oxidizing of step b) is carried out with bis(trimethylsilyl)trifluoroacetamide, trimethylsilyl chloride and trimethylsilyl peroxide.
US07/178,153 1988-04-06 1988-04-06 Phosphoramidite reagent for chemical synthesis of modified DNA Expired - Lifetime US5324831A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US07/178,153 US5324831A (en) 1988-04-06 1988-04-06 Phosphoramidite reagent for chemical synthesis of modified DNA
IL89827A IL89827A0 (en) 1988-04-06 1989-04-03 Phosphoramidite reagent for chemical synthesis of modified dna
CA000595701A CA1330960C (en) 1988-04-06 1989-04-05 Phosphoramidite reagent for chemical synthesis of modified dna
JP1504376A JPH0692435B2 (en) 1988-04-06 1989-04-06 Phosphoramidite reagent for chemical synthesis of modified DNA
AU33681/89A AU625295B2 (en) 1988-04-06 1989-04-06 Phosphoramidite reagent for chemical synthesis of modified dna
PCT/US1989/001395 WO1989009779A1 (en) 1988-04-06 1989-04-06 Phosphoramidite reagent for chemical synthesis of modified dna

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/178,153 US5324831A (en) 1988-04-06 1988-04-06 Phosphoramidite reagent for chemical synthesis of modified DNA

Publications (1)

Publication Number Publication Date
US5324831A true US5324831A (en) 1994-06-28

Family

ID=22651417

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/178,153 Expired - Lifetime US5324831A (en) 1988-04-06 1988-04-06 Phosphoramidite reagent for chemical synthesis of modified DNA

Country Status (6)

Country Link
US (1) US5324831A (en)
JP (1) JPH0692435B2 (en)
AU (1) AU625295B2 (en)
CA (1) CA1330960C (en)
IL (1) IL89827A0 (en)
WO (1) WO1989009779A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US6031091A (en) * 1987-09-21 2000-02-29 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
US6184347B1 (en) 1998-11-19 2001-02-06 Agilent Technologies Inc. Minimization of blooming in high-density arrays by using reactive wash reagents
US20020142454A1 (en) * 2001-01-26 2002-10-03 Third Wave Technologies, Inc. Nucleic acid synthesizers
US20030072689A1 (en) * 2001-08-15 2003-04-17 Third Wave Technologies, Inc. Polymer synthesizer
US20040127436A1 (en) * 2002-09-24 2004-07-01 Koronis Pharmaceuticals, Inc. 1,3,5-Triazines for treatment of viral diseases
US6762298B2 (en) 1999-03-24 2004-07-13 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile phosphorus protecting groups, associated intermediates and methods of use
US20050020827A1 (en) * 2001-12-03 2005-01-27 Beaucage Serge L. Thermolabile hydroxyl protecting groups and methods of use
US6932943B1 (en) 2001-01-26 2005-08-23 Third Wave Technologies Nucleic acid synthesizers
US20070207973A1 (en) * 2002-09-24 2007-09-06 Koronis Pharmaceuticals, Incorporated 1,3,5-Triazines for Treatment of Viral Diseases
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
US20090130455A1 (en) * 2007-10-26 2009-05-21 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
US20090263405A1 (en) * 2004-12-13 2009-10-22 Government Of The United States Of America Represented By The Secretary CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2088258C (en) * 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5574146A (en) * 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
MX2018000016A (en) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Lyophilized pharmaceutical compositions.
US10519190B2 (en) 2017-08-03 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) * 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4668777A (en) * 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
McBride et al., "Amidine Protecting Groups for Oligonucleotide Synthesis," J. Am. Chem. Soc., 1986, vol. 108, 2040-48.
McBride et al., Amidine Protecting Groups for Oligonucleotide Synthesis, J. Am. Chem. Soc., 1986, vol. 108, 2040 48. *
Piskala et. al., "Nucleic Acids Components and their Analogues Synthesis of 1-Glycoxyl Derivatives of 5-azauracil and 5-azacytosine," Coll. Czech Chem. Comm., vol. 29, pp. 2060-2076 (1964).
Piskala et. al., Nucleic Acids Components and their Analogues Synthesis of 1 Glycoxyl Derivatives of 5 azauracil and 5 azacytosine, Coll. Czech Chem. Comm., vol. 29, pp. 2060 2076 (1964). *
Tetrahedron, vol. 42, No. 2, pp. 501 513, 1986. *
Tetrahedron, vol. 42, No. 2, pp. 501-513, 1986.

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5656744A (en) * 1987-09-21 1997-08-12 Gen-Probe Incorporated Methods for making nucleotide polymers using novel linking reagents
US5696251A (en) * 1987-09-21 1997-12-09 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
US6031091A (en) * 1987-09-21 2000-02-29 Gen-Probe Incorporated Non-nucleotide linking reagents for nucleotide probes
US6184347B1 (en) 1998-11-19 2001-02-06 Agilent Technologies Inc. Minimization of blooming in high-density arrays by using reactive wash reagents
US6762298B2 (en) 1999-03-24 2004-07-13 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile phosphorus protecting groups, associated intermediates and methods of use
US6965041B1 (en) 1999-03-24 2005-11-15 The United States Of America As Represented By The Department Of Health And Human Services N-acylphosphoramidites and their use in oligonucleotide synthesis
US20080261220A1 (en) * 2000-11-30 2008-10-23 Third Wave Technologies, Inc. Nucleic Acid Detection Assays
US20020142454A1 (en) * 2001-01-26 2002-10-03 Third Wave Technologies, Inc. Nucleic acid synthesizers
US7435390B2 (en) 2001-01-26 2008-10-14 Third Wave Technologies, Inc. Nucleic acid synthesizers
US20090041634A1 (en) * 2001-01-26 2009-02-12 Third Wave Technologies, Inc. Nucleic Acid Synthesizers
US6932943B1 (en) 2001-01-26 2005-08-23 Third Wave Technologies Nucleic acid synthesizers
US20030072689A1 (en) * 2001-08-15 2003-04-17 Third Wave Technologies, Inc. Polymer synthesizer
US20050020827A1 (en) * 2001-12-03 2005-01-27 Beaucage Serge L. Thermolabile hydroxyl protecting groups and methods of use
US7355037B2 (en) 2001-12-03 2008-04-08 The United States Of America As Represented By The Department Of Health And Human Services Thermolabile hydroxyl protecting groups and methods of use
US20070142310A1 (en) * 2002-09-24 2007-06-21 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US20070207973A1 (en) * 2002-09-24 2007-09-06 Koronis Pharmaceuticals, Incorporated 1,3,5-Triazines for Treatment of Viral Diseases
US20040127436A1 (en) * 2002-09-24 2004-07-01 Koronis Pharmaceuticals, Inc. 1,3,5-Triazines for treatment of viral diseases
US7642247B2 (en) 2002-09-24 2010-01-05 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US20090263405A1 (en) * 2004-12-13 2009-10-22 Government Of The United States Of America Represented By The Secretary CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS
US9809824B2 (en) 2004-12-13 2017-11-07 The United States Of America, Represented By The Secretary, Department Of Health And Human Services CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US20090130455A1 (en) * 2007-10-26 2009-05-21 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces
US7829735B2 (en) 2007-10-26 2010-11-09 Northwestern University Universal phosphoramidite for preparation of modified biomolecules and surfaces

Also Published As

Publication number Publication date
AU3368189A (en) 1989-11-03
JPH0692435B2 (en) 1994-11-16
JPH03502577A (en) 1991-06-13
CA1330960C (en) 1994-07-26
IL89827A0 (en) 1989-12-15
AU625295B2 (en) 1992-07-09
WO1989009779A1 (en) 1989-10-19

Similar Documents

Publication Publication Date Title
US5324831A (en) Phosphoramidite reagent for chemical synthesis of modified DNA
AU712779C (en) Method for solution phase synthesis of oligonucleotides
EP0794001B1 (en) Automated system for polynucleotide synthesis and purification
US6008400A (en) Orthoester reagents for use as protecting groups in oligonucleotide synthesis
US5359052A (en) Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
EP0815114B1 (en) Nucleic acid synthesis using photoremovable protecting groups
AU737213B2 (en) Method for solution phase synthesis of oligonucleotides and peptides
EP0514513B1 (en) Method and means for oligonucleotide synthesis
WO2008037568A2 (en) Reversible terminators for efficient sequencing by synthesis
EP0753002A1 (en) Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
JPH0812697A (en) New polynucleotide
WO1998047910A1 (en) Method for solution phase synthesis of oligonucleotides
US6001966A (en) Method for solution phase synthesis of oligonucleotides and peptides
Wada et al. A new boranophosphorylation reaction for the synthesis of deoxyribonucleoside boranophosphates
WO1999051547A2 (en) Solid phase synthesis of organic compounds via phosphitylating reagents
Caruthers Synthesis of oligonucleotides and oligonucleotide analogues
Caruthers et al. Chemical and biochemical studies with dithioate DNA
Hashimoto et al. A CONVENIENT SYNTHESIS OF DINUCLEOTIDES BY OXIDATION-REDUCTION CONDENSATION USING NUCLEOSIDE 5′-PHOSPHORODIANILIDATES
US6153742A (en) General process for the preparation of cyclic oligonucleotides
AU738032B2 (en) Method for solution phase synthesis of oligonucleotides
AU5402901A (en) Method for solution phase synthesis of oligonucleotides
WO2006064039A1 (en) Synthesis of phosphitylated compounds using a quaternary heterocyclic activator

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNITED STATES OF AMERICA, THE, AS REPRESENTED BY T

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARQUEZ, VICTOR E.;REEL/FRAME:006642/0194

Effective date: 19930610

AS Assignment

Owner name: UNITED STATES OF AMERICA, THE, AS REPRESENTED BY T

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GODDARD, AMANDA J.;REEL/FRAME:006662/0413

Effective date: 19930617

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12